妊娠毒血症诊断市场规模、份额和成长分析（按检测类型、产品、最终用户和地区）- 产业预测 2025-2032

2023 年妊娠毒血症诊断市场规模价值 10.9 亿美元，预计将从 2024 年的 11.2 亿美元成长到 2032 年的 14.3 亿美元，预测期内（2025-2032 年）的复合年增长率为 3.1%。

随着人们对孕产妇健康意识的增强以及妊娠相关併发症的复杂性，全球妊娠毒血症诊断市场正在经历显着增长。妊娠毒血症是一种严重的高血压疾病，对产科护理构成重大风险，对准确和早期诊断方法的需求日益增加。因此，主要市场相关人员正在创新诊断技术，旨在改善早期检测和管理。医疗支出增加、新兴市场医疗基础设施加强、产科护理采用先进医疗技术等因素进一步推动了市场扩张。然而，挑战包括先进诊断方法的成本高昂，以及某些地区获得医疗服务的机会有限。随着新型生物标记和非侵入性诊断方法研究的进步，市场在可预见的未来可能会继续发展。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管格局
• 案例研究
• 技术进步

妊娠毒血症诊断市场规模（按检测类型和复合年增长率） (2025-2032)

• 市场概况
• 血液检查
• 尿液检查
• 其他的

妊娠毒血症诊断市场规模（按产品和复合年增长率） (2025-2032)

• 市场概况
• 装置
• 耗材

妊娠毒血症诊断市场规模（按最终用户和复合年增长率） (2025-2032)

• 市场概况
• 医院
• 专科门诊
• 诊断中心
• 其他的

妊娠毒血症诊断市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司详细信息
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Diabetomics Inc.（United States）
• DRG Instruments GmbH（Germany）
• F. Hoffmann-La Roche Ltd（Switzerland）
• PerkinElmer Inc.（United States）
• Siemens Healthineers AG（Germany）
• Thermo Fisher Scientific（United States）
• GE Healthcare（United States）
• Abbott Laboratories（United States）
• Acon Laboratories, Inc.（United States）
• Arkray, Inc.（Japan）
• Bio-Rad Laboratories, Inc.（United States）
• Cardinal Health（United States）
• Danaher Corporation（Beckman Coulter, Inc.）（United States）
• DIRUI Industrial Co., Ltd.（China）
• Metabolomic Diagnostics Ltd.（Ireland）
• Sera Prognostics（United States）
• Synlab Group（Germany）
• Microlife Corporation（Switzerland）
• Bayer AG（Germany）
• Progenity Inc.（United States）

结论和建议

Preeclampsia Diagnostics Market size was valued at USD 1.09 billion in 2023 and is poised to grow from USD 1.12 billion in 2024 to USD 1.43 billion by 2032, growing at a CAGR of 3.1% during the forecast period (2025-2032).

The global preeclampsia diagnostics market is experiencing significant growth, driven by heightened awareness surrounding maternal health and the complexities of pregnancy-related complications. As preeclampsia, a serious hypertensive condition, poses substantial risks in obstetrics, the demand for precise and early diagnostic methods is escalating. Consequently, major market players are innovating diagnostic technologies aimed at improving early detection and management. Factors such as rising healthcare expenditures, enhancements in healthcare infrastructure in emerging markets, and the incorporation of advanced medical technologies in obstetric care are further propelling market expansion. However, high costs of sophisticated diagnostic methods and limited healthcare access in certain regions may pose challenges. With ongoing research into novel biomarkers and non-invasive diagnostics, the market is poised for continued advancements in the foreseeable future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Preeclampsia Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Preeclampsia Diagnostics Market Segments Analysis

Global Preeclampsia Diagnostics Market is segmented by Test Type, Product, End-user and region. Based on Test Type, the market is segmented into Blood Tests, Urine Analysis and Others. Based on Product, the market is segmented into Instruments and Consumables. Based on End-user, the market is segmented into Hospitals, Specialty Clinics, Diagnostic Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Preeclampsia Diagnostics Market

The Preeclampsia Diagnostics market is driven by the challenges associated with accurately diagnosing the condition in pregnant women. A solitary increase in blood pressure is not a definitive indicator of preeclampsia, complicating the diagnosis process. Furthermore, many expectant mothers lack awareness of preeclampsia and its associated risks, which can lead to hypertension during pregnancy going undetected until it escalates, thereby restricting timely intervention opportunities. This gap in knowledge not only poses significant health risks to the women affected but also heightens the likelihood of increased infant mortality rates, underscoring the urgent need for effective diagnostic solutions and education.

Restraints in the Preeclampsia Diagnostics Market

The preeclampsia diagnostics market faces significant challenges due to the complexities involved in diagnosing the condition in pregnant women. A mere increase in blood pressure is not a definitive indicator of preeclampsia, making accurate identification difficult. Furthermore, a considerable number of expectant mothers lack knowledge about preeclampsia, which severely limits their understanding of the associated risks. As hypertension often goes undetected until more severe symptoms arise, this oversight restricts timely intervention options. The resultant unawareness poses considerable risks to maternal health and significantly heightens infant mortality rates, emphasizing the critical need for improved awareness and diagnostic methods in this area.

Market Trends of the Preeclampsia Diagnostics Market

The global preeclampsia diagnostics market is witnessing a significant trend towards early risk assessment for pregnant women, propelling the adoption of biomarker-based tests designed for the early detection of this condition. By focusing on specific biological markers, healthcare providers can more accurately identify potential preeclampsia cases, which enables timely interventions crucial for improving maternal and fetal health outcomes. This proactive diagnostic approach aligns with the overarching goals of healthcare systems to enhance maternal care and reduce the adverse effects of preeclampsia on pregnancies. As awareness and demand for early intervention grow, the market for innovative diagnostic solutions is expected to flourish in tandem.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Preeclampsia Diagnostics Market Size by Test Type & CAGR (2025-2032)

• Market Overview
• Blood Tests
• Urine Analysis
• Others

Global Preeclampsia Diagnostics Market Size by Product & CAGR (2025-2032)

• Market Overview
• Instruments
• Consumables

Global Preeclampsia Diagnostics Market Size by End-user & CAGR (2025-2032)

• Market Overview
• Hospitals
• Specialty Clinics
• Diagnostic Centers
• Others

Global Preeclampsia Diagnostics Market Size & CAGR (2025-2032)

• North America (Test Type, Product, End-user)
  • US
  • Canada
• Europe (Test Type, Product, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Test Type, Product, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Test Type, Product, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Test Type, Product, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Diabetomics Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DRG Instruments GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acon Laboratories, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arkray, Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cardinal Health (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (Beckman Coulter, Inc.) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DIRUI Industrial Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Metabolomic Diagnostics Ltd. (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sera Prognostics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Synlab Group (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Microlife Corporation (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Progenity Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations